10x Genomics, Inc. (NASDAQ:TXG) Insider Benjamin J. Hindson Sells 4,573 Shares

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

10x Genomics Stock Performance

Shares of TXG opened at $10.69 on Friday. 10x Genomics, Inc. has a 1 year low of $10.40 and a 1 year high of $48.42. The company’s 50 day simple moving average is $14.00 and its 200 day simple moving average is $16.81. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -7.03 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Trading of 10x Genomics

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in shares of 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock worth $8,027,000 after buying an additional 277,355 shares during the period. Entropy Technologies LP grew its position in shares of 10x Genomics by 285.6% in the fourth quarter. Entropy Technologies LP now owns 37,595 shares of the company’s stock valued at $540,000 after purchasing an additional 27,844 shares during the last quarter. Geode Capital Management LLC grew its position in 10x Genomics by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock worth $41,009,000 after buying an additional 42,777 shares in the last quarter. SG Americas Securities LLC boosted its holdings in 10x Genomics by 209.8% during the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock valued at $1,049,000 after purchasing an additional 49,468 shares in the last quarter. Finally, Alberta Investment Management Corp acquired a new stake in 10x Genomics during the fourth quarter valued at approximately $3,206,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TXG has been the topic of a number of analyst reports. Leerink Partners cut 10x Genomics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Barclays lowered their target price on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Stifel Nicolaus reduced their price target on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group cut their target price on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.57.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.